HK1258509A1 - Gitr激動劑 - Google Patents
Gitr激動劑Info
- Publication number
- HK1258509A1 HK1258509A1 HK19100858.0A HK19100858A HK1258509A1 HK 1258509 A1 HK1258509 A1 HK 1258509A1 HK 19100858 A HK19100858 A HK 19100858A HK 1258509 A1 HK1258509 A1 HK 1258509A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- gitr agonists
- gitr
- agonists
- Prior art date
Links
- 101100425749 Mus musculus Tnfrsf18 gene Proteins 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562245188P | 2015-10-22 | 2015-10-22 | |
| US201662276352P | 2016-01-08 | 2016-01-08 | |
| PCT/EP2016/075558 WO2017068186A1 (en) | 2015-10-22 | 2016-10-24 | Gitr agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1258509A1 true HK1258509A1 (zh) | 2019-11-15 |
Family
ID=57211500
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK19100858.0A HK1258509A1 (zh) | 2015-10-22 | 2019-01-17 | Gitr激動劑 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11059899B1 (zh) |
| EP (1) | EP3365371A1 (zh) |
| JP (1) | JP7084870B2 (zh) |
| CN (1) | CN108473579B (zh) |
| AU (1) | AU2016341403B2 (zh) |
| CA (1) | CA3002711A1 (zh) |
| HK (1) | HK1258509A1 (zh) |
| WO (1) | WO2017068186A1 (zh) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6913682B2 (ja) * | 2015-07-23 | 2021-08-04 | インヒブリックス， インコーポレイテッド | 多価および多重特異性ｇｉｔｒ結合融合タンパク質 |
| JP7084870B2 (ja) | 2015-10-22 | 2022-06-15 | アブリンクス エン．ヴェー． | Ｇｉｔｒアゴニスト |
| SG11201810023QA (en) | 2016-05-27 | 2018-12-28 | Agenus Inc | Anti-tim-3 antibodies and methods of use thereof |
| JP2019519536A (ja) | 2016-07-01 | 2019-07-11 | ファイブ プライム セラピューティクス， インコーポレイテッド | Ｇｉｔｒアゴニストおよびｃｐｇを用いた組み合わせ抗腫瘍療法 |
| TWI773694B (zh) | 2016-10-11 | 2022-08-11 | 美商艾吉納斯公司 | 抗ｌａｇ－３抗體及其使用方法 |
| KR20200006115A (ko) | 2017-05-16 | 2020-01-17 | 브리스톨-마이어스 스큅 컴퍼니 | 항-gitr 효능제 항체에 의한 암의 치료 |
| US20200131263A1 (en) | 2017-06-30 | 2020-04-30 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-gitr antibody, antigen-binding fragment thereof, and pharmaceutical use thereof |
| CN110357958A (zh) * | 2018-03-26 | 2019-10-22 | 信达生物制药(苏州)有限公司 | 抗糖皮质激素诱导的肿瘤坏死因子受体(gitr)的小型化抗体、其聚合物及应用 |
| CN113150141B (zh) * | 2018-06-06 | 2022-02-18 | 暨南大学 | 一种抗重组人碱性成纤维细胞生长因子纳米抗体及其应用 |
| RU2734432C1 (ru) | 2019-04-23 | 2020-10-16 | Закрытое Акционерное Общество "Биокад" | Моноклональное антитело, которое специфически связывается с GITR |
| CA3163877A1 (en) * | 2019-12-06 | 2021-06-10 | Ablynx Nv | Polypeptides comprising immunoglobulin single variable domains targeting tnf.alpha. and il-23 |
| KR20230074527A (ko) * | 2020-09-25 | 2023-05-30 | 아블린쓰 엔.브이. | Il-13 및 ox40l을 표적으로 하는 면역글로불린 단일 가변 도메인을 포함하는 폴리펩티드 |
| US11897951B2 (en) | 2020-12-18 | 2024-02-13 | Ablynx N.V. | Polypeptides comprising immunoglobulin single variable domains targeting IL-6 and TNF-α |
| CN112851811B (zh) * | 2021-01-28 | 2022-08-09 | 姜国胜 | 一种cd44v6纳米抗体及其作为白血病研究试剂的应用 |
| WO2022240161A1 (ko) * | 2021-05-10 | 2022-11-17 | 메디맵바이오 주식회사 | 항-gitr 항체 및 이의 용도 |
| WO2023213763A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab |
| WO2023213764A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf |
| WO2024003353A1 (en) | 2022-07-01 | 2024-01-04 | Transgene | Fusion protein comprising a surfactant-protein-d and a member of the tnfsf |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1809589A (zh) * | 2003-05-23 | 2006-07-26 | Wyeth公司 | Gitr配体和gitr配体相关分子和抗体及其应用 |
| DK1866339T3 (da) | 2005-03-25 | 2013-09-02 | Gitr Inc | GTR-bindende molekyler og anvendelser heraf |
| CN101218257A (zh) * | 2005-03-25 | 2008-07-09 | 托勒克斯股份有限公司 | Gitr结合分子及其用途 |
| CN102574924A (zh) | 2009-09-03 | 2012-07-11 | 先灵公司 | 抗-gitr抗体 |
| TW201605896A (zh) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | Gitr抗原結合蛋白 |
| IL293212B2 (en) * | 2014-05-28 | 2023-12-01 | Memorial Sloan Kettering Cancer Center | Anti-GITR antibodies and methods of using them |
| KR101923326B1 (ko) | 2014-06-06 | 2018-11-29 | 브리스톨-마이어스 스큅 컴퍼니 | 글루코코르티코이드-유도 종양 괴사 인자 수용체 (gitr)에 대한 항체 및 그의 용도 |
| CA2988115A1 (en) | 2015-06-03 | 2016-12-08 | Bristol-Myers Squibb Company | Anti-gitr antibodies for cancer diagnostics |
| JP6913682B2 (ja) * | 2015-07-23 | 2021-08-04 | インヒブリックス， インコーポレイテッド | 多価および多重特異性ｇｉｔｒ結合融合タンパク質 |
| JP7084870B2 (ja) | 2015-10-22 | 2022-06-15 | アブリンクス エン．ヴェー． | Ｇｉｔｒアゴニスト |
-
2016
- 2016-10-24 JP JP2018520394A patent/JP7084870B2/ja active Active
- 2016-10-24 CN CN201680075294.1A patent/CN108473579B/zh active Active
- 2016-10-24 US US15/769,205 patent/US11059899B1/en active Active
- 2016-10-24 WO PCT/EP2016/075558 patent/WO2017068186A1/en active Application Filing
- 2016-10-24 AU AU2016341403A patent/AU2016341403B2/en active Active
- 2016-10-24 CA CA3002711A patent/CA3002711A1/en active Pending
- 2016-10-24 EP EP16788484.0A patent/EP3365371A1/en active Pending
-
2019
- 2019-01-17 HK HK19100858.0A patent/HK1258509A1/zh unknown
-
2021
- 2021-05-14 US US17/320,395 patent/US11919966B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017068186A9 (en) | 2017-06-22 |
| US11919966B2 (en) | 2024-03-05 |
| CA3002711A1 (en) | 2017-04-27 |
| AU2016341403A1 (en) | 2018-05-10 |
| JP2018537421A (ja) | 2018-12-20 |
| WO2017068186A1 (en) | 2017-04-27 |
| US20220411521A1 (en) | 2022-12-29 |
| US11059899B1 (en) | 2021-07-13 |
| CN108473579B (zh) | 2022-03-01 |
| CN108473579A (zh) | 2018-08-31 |
| AU2016341403B2 (en) | 2023-08-03 |
| JP7084870B2 (ja) | 2022-06-15 |
| EP3365371A1 (en) | 2018-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1258509A1 (zh) | Gitr激動劑 | |
| DK3389557T3 (en) | Transseptalt leveringssystem | |
| DK3320033T3 (en) | Polyethylenterephthalat-depolymerisering | |
| DK3256579T3 (en) | Cysteinprotease | |
| DK3256580T3 (en) | Cysteinprotease | |
| DK3250592T3 (en) | Anti-transthyretin-antistoffer | |
| DK3373882T3 (en) | Patientisolator | |
| GB201509585D0 (en) | - | |
| DK3284069T3 (en) | Pos-terminal | |
| DK3390996T3 (en) | Trykbart tids-temperaturindikatorsystem | |
| DK3380145T3 (en) | Injektionsapparat | |
| DK3336185T3 (en) | Antistof | |
| DK3272750T3 (en) | Morphinan-derivat | |
| DK3324768T3 (en) | Tørdragt | |
| AU361999S (en) | Ballustrade | |
| DK3133099T3 (en) | Polymermodificeret polyoldispersion | |
| DK3282866T3 (en) | Proteinfibre | |
| DK3250312T3 (en) | Urea-metalnitrat-scr-system | |
| DK3294653T3 (en) | Justerbar inline-port | |
| GB201511951D0 (en) | An eyeguard | |
| GB201502316D0 (en) | Bitcon technology | |
| DK3242882T3 (en) | Cgrp-antagonistpeptider | |
| GB201502073D0 (en) | HDEG technology | |
| GB201500297D0 (en) | Agonists | |
| ZA201507180B (en) | An overall |